- Home
- JTAI vs BDRX Comparison
JTAI vs BDRX Comparison
Compare JTAI & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JTAI | BDRX |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JTAI | BDRX |
|---|---|---|
| Price | $0.64 | $2.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 2.8M |
| Earning Date | 11-14-2025 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,584,279.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $433.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $2.22 |
| 52 Week High | $11.77 | $92.00 |
Technical Indicators
Market Signals| Indicator | JTAI | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 23.63 | 38.94 |
| Support Level | $0.52 | $2.22 |
| Resistance Level | $0.80 | $7.22 |
| Average True Range (ATR) | 0.18 | 0.71 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 10.66 | 4.60 |
Price Performance
Historical ComparisonAbout JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.